{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-021937","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.795899+00:00","generated_at":"2026-06-12T07:40:45.086402+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Puma Biotechnology Q2 net income $2.1M, down from $9.4M YoY; revenue flat at $51.6M","bullets":["GAAP net income $2.1M ($0.05/diluted share) vs $9.4M ($0.21) Q2 2022; non-GAAP adj net income $4.6M ($0.10).","Product revenue from NERLYNX $51.6M, slightly up from $51.3M YoY; royalty revenue fell to $3.0M from $8.2M.","Net cash from operations positive $3.3M vs -$13.9M Q2 2022; cash & securities $74.4M at June 30.","FY 2023 guidance: product revenue $205-210M, net income $20-24M; Q3 product revenue guided $51-53M.","Pipeline milestones: Phase II alisertib in small cell lung cancer H2 2023; FDA meeting Q4 for HR+ HER2- breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-021937","json":"https://secwatch.observer/filing/0001437749-23-021937.json","markdown":"https://secwatch.observer/filing/0001437749-23-021937.md","text":"https://secwatch.observer/filing/0001437749-23-021937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/0001437749-23-021937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/pbyi20230731_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:40:45.086402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"732b94238ada0b3cfca282ac0e5fc5be9c5a8c01","claim":"PUMA BIOTECHNOLOGY, INC. reported the second quarter ended June 30, 2023 results: revenue $51.6 million, net income $2.1 million, EPS $0.05 per basic and diluted share.","evidence_excerpt":"Product revenue, net in the second quarter of 2023 was $51.6 million, an increase from $51.3 million reported for the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/0001437749-23-021937-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$51.6 million"},{"label":"Net income","value":"$2.1 million"},{"label":"EPS","value":"$0.05 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a97ac433e70c037c6a397880d625adc3de991231","claim":"PUMA BIOTECHNOLOGY, INC. reported the first six months of 2023 results: revenue $98.3 million, net income $3.5 million, EPS $0.08 per basic share and $0.07 per diluted share.","evidence_excerpt":"Product revenue, net in the first six months of 2023 was $98.3 million, compared to $92.0 million in the first six months of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/0001437749-23-021937-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first six months of 2023"},{"label":"Revenue","value":"$98.3 million"},{"label":"Net income","value":"$3.5 million"},{"label":"EPS","value":"$0.08 per basic share and $0.07 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}